An Open-labeled Phase I Clinical Trial Evaluating the Safety, Tolerability, Biodistribution Characteristics, Biological EEffects, and Initial Efficacy of VRT106 for Injection in the Treatment of Locally Advanced/Metastatic Solid Tumors by Intravenous Administration
Latest Information Update: 19 Feb 2025
At a glance
- Drugs VRT-106 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Guangzhou Virotech Pharmaceutical
- 19 Feb 2025 New trial record